Biocon reported a 73% drop in profit for FY26 to ₹385.6 crore, despite a 5% increase in total income to ₹17,269.5 crore. The company recommended a dividend of ₹0.50 per share.
Biocon Reports FY26 Results: Income Rises, Profit Dips Sharply
Biocon's Total Income for FY2026 reached ₹17,269.5 crore, a 5% increase from FY2025. However, its Profit for the year saw a significant decline of 73%, falling to ₹385.6 crore in FY2026 from ₹1,429.4 crore in FY2025. The company announced a recommended final dividend of ₹0.50 per share.
Reader Takeaway: Integration benefits drive revenue; profit hit by acquisition costs & muted CRDMO growth.
What just happened
Biocon Ltd. has released its consolidated financial results for the fiscal year ended March 31, 2026. Total income rose by 5% to ₹17,269.5 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹3,797.8 crore, with an EBITDA margin of 22%. The profit for the year, however, dropped by a substantial 73% to ₹385.6 crore.
Why this matters
The sharp decline in profit, despite revenue growth, indicates significant factors impacting the bottom line, likely related to the full consolidation of Biocon Biologics and potential one-off expenses. The dividend announcement shows a continued commitment to shareholder returns.
The backstory
Biocon's performance in FY26 is marked by the full consolidation of Biocon Biologics. This strategic move aimed to simplify the corporate structure and enhance earnings visibility. The company has been focused on integrated growth and deleveraging post-acquisition phases.
What changes now
The company has appointed Shreehas Tambe as the new CEO & MD, effective April 1, 2026, succeeding Siddharth Mittal. This leadership transition aligns with the company's strategic direction. The 48th Annual General Meeting is scheduled for August 6, 2026.
Risks to watch
A key concern is the muted 3% growth in the CRDMO segment, attributed to transient customer-specific challenges. Geopolitical risks are also a watch point, with potential impacts on the supply chain and global operations.
Peer comparison
(Data not available in the filing)
Context metrics (time-bound)
- Total Income (FY26): ₹17,269.5 crore
- Profit for the year (FY26): ₹385.6 crore
- EBITDA (FY26): ₹3,797.8 crore
- Capital expenditure (FY26): ₹1,911.7 crore
- Net debt (FY26): ₹10,416.8 crore
- Net debt-to-EBITDA ratio (FY26): 2.7x
What to track next
Investors should monitor the successful integration benefits of Biocon Biologics, progress on debt reduction, and the performance turnaround of the CRDMO business in FY27. The company's ability to navigate geopolitical risks and operational challenges will be crucial.